Abstract:Funding Acknowledgements Type of funding sources: Foundation. Main funding source(s): Leducq Foundation Background Doxorubicin (DOX) is an anthracycline chemotherapeutic agent whose clinical application is hindered by the emergence of early and late cardiotoxic effects. Recent findings demonstrated that DOX damages cardiac mitochondria, with subsequent metabolic perturbation and energetic imbalance. We previously observed that phosphoinositide 3-kinase γ (PI3Kγ) contributes to DOX-induced cardiotoxicity, mediating mitophagy inhibition and accumulation of damaged mitochondria into cardiac cells. Objective Here we intend to describe the cardiotoxic metabolic phenotype of DOX-treated hearts, unravelling the contribution of PI3Kγ signalling to this process. Methods Wild-type (WT) and knock-in mice expressing a kinase-inactive PI3Kγ (kinase-dead; KD) were treated with DOX at day 0, 7 and 14 (cumulative dose 12 mg/kg). To explore the contribution of PI3Kγ on the early cardiac metabolic rewiring, metabolomic analysis, mitochondrial respiration capacity and glycolytic enzymes activity were evaluated at day 3. To investigate the role of autophagy, mice were infected with an adeno-associated virus 9 (AAV9) carrying a vector expressing a short-hairpin RNA against ATG7 (ATG7sh). To test the role of PI3Kγ in glycolysis regulation, glucose uptake and plasma membrane exposure of GLUT-4 were measured in neonatal mouse cardiomyocytes with DOX acute treatment (1μM for 3h). To evaluate the contribution of different substrates to oxygen consumption, OROBOROS analysis were performed on myocardial slices from mice sacrificed at day 3 and 42. Results DOX-treated cardiomyocytes exhibited a metabolic phenotype characterized by glucose as the primary energy substrate, with increased uptake and augmented glycolytic enzymes activity. Metabolomic analysis of DOX-treated hearts indicated diminished pyruvate levels, the glycolysis end-product, unaltered lactate but increased Acetyl-CoA quantity, suggesting enhanced glucose processing for the TCA cycle. Accordingly, oxygen consumption after pyruvate supplementation significantly increased in DOX-treated condition, resulting in the generation of cytotoxic ROS rather than energy production. This was mainly due to DOX-induced mitochondrial damage, with impaired fatty acid oxidation and electron transport chain activity, resulting in TCA cycle slow-down, with accumulation of cardiotoxic glucose-derived intermediates. These metabolic alterations were completely prevented in KD hearts. In vitro experiments demonstrated that inhibiting PI3Kγ reduced the activity of pyruvate dehydrogenase (PDH), the key enzyme of Randle cycle, regulating the switch from fatty acids to glucose usage, while decreasing DOX-induced mobilization of GLUT-4-carrying vesicles to the plasma membrane, limiting subsequent glucose uptake. Conclusion These results demonstrate that DOX promotes an early metabolic rewiring with PI3Kγ-dependent increased glucose uptake and modulation of the Randle cycle towards augmented glucose utilization.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is: **To explore the metabolic adaptation mechanisms behind the early - and late - stage cardiotoxicity caused by doxorubicin (DOX), especially the role of phosphatidylinositol 3 - kinase γ (PI3Kγ) in this process**. ### Background Doxorubicin is an anthracycline chemotherapeutic drug, and its clinical application is limited by early - and late - stage cardiotoxicity. Studies have shown that DOX can damage myocardial mitochondria, leading to metabolic disorders and energy imbalance. Previous studies have found that PI3Kγ is involved in DOX - induced cardiotoxicity by inhibiting mitophagy and causing the accumulation of damaged mitochondria in cardiomyocytes. ### Objectives This paper aims to describe the characteristics of metabolic changes in the heart after DOX treatment and to reveal the contribution of the PI3Kγ signaling pathway in this process. ### Methods 1. **Animal experiments**: - Use wild - type (WT) and mice expressing kinase - dead PI3Kγ (kinase - dead; KD). - Mice receive DOX treatment (cumulative dose of 12 mg/kg) on day 0, day 7, and day 14, and metabolicomics analysis, mitochondrial respiratory capacity, and glycolytic enzyme activity assessment are carried out on day 3. 2. **Autophagy study**: - Use adeno - associated virus 9 (AAV9) carrying short - hairpin RNA (shRNA) targeting ATG7 to infect mice to study the role of autophagy. 3. **Role of PI3Kγ in glycolysis regulation**: - Measure glucose uptake and GLUT - 4 exposure to the plasma membrane in neonatal mouse cardiomyocytes, with acute DOX treatment (1 µM, 3 hours). 4. **Effect of substrates on oxygen consumption**: - Use the OROBOROS analysis method to measure the contribution of different substrates to oxygen consumption in myocardial slices of mice sacrificed on day 3 and day 42. ### Results - Cardiomyocytes after DOX treatment show a metabolic phenotype with glucose as the main energy substrate, with increased glucose uptake and enhanced glycolytic enzyme activity. - Metabolicomics analysis shows that the pyruvate level is decreased, the lactate level is unchanged, and the acetyl - coenzyme A level is increased in the DOX - treated heart, indicating that more glucose enters the tricarboxylic acid cycle (TCA cycle). - After supplementing pyruvate, oxygen consumption under DOX - treatment conditions is significantly increased, but mainly generates cytotoxic reactive oxygen species (ROS) rather than energy production. This is mainly due to mitochondrial damage caused by DOX, resulting in impaired fatty acid oxidation and electron transport chain activity, a slowdown of the TCA cycle, and the accumulation of toxic glucose derivatives. - These metabolic changes are completely prevented in KD hearts. - In vitro experiments show that inhibiting PI3Kγ can reduce the activity of pyruvate dehydrogenase (PDH), regulate the Randle cycle, and reduce the mobilization of DOX - induced GLUT - 4 vesicles to the plasma membrane, thereby limiting subsequent glucose uptake. ### Conclusions These results indicate that DOX promotes early - stage metabolic reprogramming, with an increase in glucose uptake depending on PI3Kγ and the regulation of the Randle cycle, resulting in an increase in glucose utilization. --- Through the above research, the authors hope to reveal the metabolic mechanisms behind DOX - induced cardiotoxicity and provide a theoretical basis for the development of new treatment strategies.

Exploring the mechanisms of metabolic adaptations to cardiotoxic doxorubicin

Unravelling the metabolic rewiring in the context of doxorubicin-induced cardiotoxicity: Fuel preference changes from fatty acids to glucose oxidation

Initial Phase of Anthracycline Cardiotoxicity Involves Cardiac Fibroblasts Activation and Metabolic Switch

Metabolic remodeling associated with subchronic doxorubicin cardiomyopathy

Small-molecule mediated MuRF1 inhibition protects from doxorubicin-induced cardiac atrophy and contractile dysfunction

The Metabolic Fingerprint of Doxorubicin-Induced Cardiotoxicity in Male CD-1 Mice Fades Away with Time While Autophagy Increases

Interrogating early molecular events of doxorubicin-induced cardiotoxicity at single-cell level to identify new cardioprotective agents

Metabolic Effects of Doxorubicin on the Rat Liver Assessed With Hyperpolarized MRI and Metabolomics

Doxorubicin In Vivo Rapidly Alters Expression And Translation Of Myocardial Electron Transport Chain Genes, Leads To Atp Loss And Caspase 3 Activation

Mitochondrial Responses to Sublethal Doxorubicin in H9c2 Cardiomyocytes: The Role of Phosphorylated CaMKII

Insights into Doxorubicin-Induced Cardiotoxicity

Doxorubicin downregulates autophagy to promote apoptosis-induced dilated cardiomyopathy via regulating the AMPK/mTOR pathway

Inhibition of AMPK signalling by doxorubicin: at the crossroads of the cardiac responses to energetic, oxidative, and genotoxic stress.

The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity

Disruption of the Keap1/Nrf2-Antioxidant Response System After Chronic Doxorubicin Exposure In Vivo

Differential Impact of Doxorubicin Dose on Cell Death and Autophagy Pathways during Acute Cardiotoxicity

Role of mitochondria in doxorubicin-mediated cardiotoxicity: From molecular mechanisms to therapeutic strategies

Infiltrating macrophages amplify doxorubicin-induced cardiac damage: role of catecholamines

Doxorubicin-induced cardiotoxicity involves IFNγ-mediated metabolic reprogramming in cardiomyocytes

Comparative In Vitro Study of the Cytotoxic Effects of Doxorubicin's Main Metabolites on Cardiac AC16 Cells Versus the Parent Drug